Please ensure Javascript is enabled for purposes of website accessibility

Can This Forgotten Coronavirus Stock Make You Rich?

By Prosper Junior Bakiny - May 25, 2021 at 10:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite strong headwinds, there may be hope for this biotech.

Last year, biotech company Gilead Sciences (GILD 0.27%) rose in prominence thanks to antiviral medicine Veklury, which was sometimes touted as the most promising potential treatment for COVID-19. But a lot has happened since then for the drugmaker, and in the past 12 months, Gilead Sciences' stock has underperformed the broader market, as the following graph illustrates.

This poor showing does have one silver lining, though. Shares of Gilead Sciences are reasonably valued at 9.7 times forward earnings, compared with an estimated forward price-to-earnings ratio of 21 for the S&P 500. If there is a rebound in the cards for the biotech -- and if it can soundly beat the market from here on out -- initiating a position in Gilead Sciences at current prices will pay rich dividends down the road. 

GILD Chart

GILD data by YCharts

With that said, how likely is a strong comeback for Gilead Sciences?

Here's what went wrong

A series of factors caused Gilead Sciences' lackluster performance in the past year. Perhaps the most important was the debacle surrounding filgotinib. The company -- and many analysts -- once regarded this potential rheumatoid arthritis (RA) drug as a future blockbuster. However, in August, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) had declined to approve the drug. 

The reason? The FDA had concerns surrounding filgotinib's potential impact on sperm count. In December, Gilead Sciences decided it would no longer pursue FDA approval for filgotinib as a treatment for RA in the United States. Up to that point, some investors had remained hopeful that the company would work things out with regulators. This disappointing outcome was a non-negligible blow to Gilead Sciences' prospects. 

Veklury to the rescue 

The filgotinib-related drama aside, Gilead Sciences has other problems. For instance, the company's HIV franchise -- which was supposed to be its saving grace -- seems to be struggling. In the first quarter ending March 31, the company's HIV business racked up $3.7 billion in revenue, 12% lower than the year-ago period. The decrease was largely caused by declining sales of Truvada -- one of its best-selling HIV drugs -- which in turn came from the loss of exclusivity on the medicine.

Nurse with her hand on her chin and a pensive expression.

Image source: Getty Images.

While sales of Biktarvy, Gilead Sciences' top-selling HIV drug, jumped by 8% year over year to $1.8 billion, that wasn't enough to keep the company's revenue from its HIV franchise from declining compared to the prior-year quarter. The pandemic is also an important factor behind the lower revenue for several of its business segments, including HIV. Despite these headwinds, Gilead Sciences recorded total revenue of $6.4 billion, 16% higher than in the first quarter of the previous fiscal year.

Along with Biktarvy, the company had revenue of $1.5 billion from Veklury to thank for that. Excluding sales of the COVID-19 medicine, the company's total revenue dropped by 11% year over year to $4.9 billion. According to management, 50% of hospitalized COVID-19 patients in the U.S. are treated with Veklury, and it's also popular in international markets. Gilead Sciences expects sales of Veklury to reach between $2 billion and $3 billion for the full fiscal year.

The coronavirus medicine will lose steam as the pandemic subsides. But Gilead Sciences' other businesses should pick up, thereby providing a nice boost to its revenue. The biotech can also rely on its cancer medicine, Trodelvy. In the first quarter, sales of this drug came in at only $72 million; it was the first full quarter of revenue recognition for the product.

But in April alone, Trodelvy earned FDA approval for metastatic breast cancer and metastatic urothelial cancer. The drug is still undergoing other clinical trials, and Gilead Sciences sees a massive market opportunity made up of well over 50,000 cancer patients in the U.S. alone. Trodelvy could become a key growth driver for Gilead Sciences in the future. 

Is it a buy?

Gilead Sciences has more than three dozen clinical programs in its pipeline, and it recently entered into a partnership with pharma giant Merck to co-develop HIV treatments. The biotech looks set to continue adding to its lineup. I have no doubts that Gilead Sciences' revenue, excluding Veklury, will eventually start growing again.

And while I think the biotech company is likely to perform better in the market from here on out, I don't think Gilead Sciences is in a position to deliver market-shattering returns. If you're looking for a stock that will make you rich over the next decade or so, there are much better options. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.62 (0.27%) $0.17
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$89.89 (1.08%) $0.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.